Jasper Therapeutics, Inc. (JSPRW) Stock Price & Analysis

Jasper Therapeutics, Inc. (JSPRW) fell 19.57% to USD 0.01 as of September 9, 2026 at 13:28 UTC, according to Nexqual real-time market data.

JSPRW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 506 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, September 9, 2026 at 13:28 UTC.

Key Statistics (as of September 9, 2026 at 13:28 UTC)

From Jasper Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Patent Application Serial Number 12/447,634 (publication number US 2010/0226927 Al) and know-how for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated.    Intellectual Property   Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates and other discoveries, inventions, trade secrets and know-how that are critical to our business operations.
• It also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights.

Partnerships

• We expect to continue to broaden our pipeline with additional mast cell indications.    We have an exclusive license agreement with Amgen Inc. ("Amgen") for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide.
• The issued U.S. patents would be expected to expire in 2027, absent any applicable patent term extensions.   License Agreement with Stanford   In March 2021, we entered into an exclusive license agreement with respect to the use of briquilimab from the Stanford Office of Technology Licensing to license U.S.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 13:28 UTC. This page is informational and not investment advice.